Typing TPMT and ITPase to detect azathioprine toxicity

Personalized Medicine

Volumn 3, Issue 1, 2006, Pages 45-59

  Arenas, Monica ^a   Marinaki, Anthony ^a   Ansari, Azhar ^b   Sanderson, Jeremy ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

6 mercaptopurine; Adverse effects; Azathioprine; Drug toxicity; Inflammatory bowel disease; Inosine triphosphatase; Inosine triphosphate pyrophosphohydrolase; ITPA; ITPase; Thiopurine; Thiopurine methyl transferase; TPMT

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALDEHYDE OXIDASE; ALLOPURINOL; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLIZING ENZYME; IMMUNOSUPPRESSIVE AGENT; INOSINE TRIPHOSPHATASE; KETOCONAZOLE; MESALAZINE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ACUTE PANCREATITIS; ARTHRITIS; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME INHIBITION; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HUMAN; INFECTION; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; WITHDRAWAL SYNDROME; XANTHINURIA;

EID: 33646801256     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.1.45     Document Type: Review

References (110)

1. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302(18), 981-987 (1980).
2. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2, CD000067 (2000).
3. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343(8907), 1188-1190 (1994).
4. Scerri L: Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv. Exp. Med. Biol. 455, 343-348 (1999).
5. Ansari A, Hassan C, Duley J et al.: Thiopurine methyltransferase activity and the use of azathioprine In inflammatory bowel disease. Aliment. Pharmacol. Ther. 16(10), 1743-1750 (2002).
6. Bajaj JS, Saeian K, Varma RR et al.: Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100(5), 1121-1125 (2005).
7. Suarez-Almazor ME, Spooner C, Belseck E: Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 4, CD001461 (2000).
8. Pearson D: Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 123, 132-142 (1995).
9. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI: 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. 111(8), 641-649 (1989).
10. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34(8), 1081-1085 (1993).
11. Haber CJ, Meltzer SJ, Present DH, Korelitz BI: Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 91(4), 982-986 (1986).
12. Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM: Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React. Toxicol. Rev. 19(4), 293-312 (2000).
13. Weersma RK, Peters FT, Oostenbrug LE et al.: Increased Incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol. Ther. 20(8), 843-850 (2004).
14. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000545 (2000).
15. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA: Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13(8), 563-567 (2004).
16. Alexander S, Dowling D: Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern. Med. J. 35(9), 570-571 (2005).
17. Boulton-Jones JR, Pritchard K, Mahmoud AA: The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 14(12), 1561-1565 (2000).
18. Bowen DG, Selby WS: Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig. Dis. Sci. 45(9), 1810-1813 (2000).
19. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR: Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122(3), 838-839 (2002).
20. Dubinsky MC, Yang H, Hassard PV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122(4), 904-915 (2002).
21. Goldenberg BA, Rawsthorne P, Bernstein CN: The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 99(9), 1744-1748 (2004).
22. Elion GB: Symposium on immunosuppresive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc 26, 898-904 (1967).
23. Scannell JP, Hitchings GH: Thioguanine in deoxyribonucleic acid from tumors of 6-mercaptopurine-treated mice. Proc. Soc. Exp. Boil. Med. 122(3), 627-629 (1966).
24. Tiede I. Fritz G, Strand S et al.: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111(8), 1133-1145 (2003).
25. Coulthard SA, Hogarth LA, Little M et al.: The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol. 62(1), 102-109 (2002).
26. Weinshilboum RM, Otterness DM, Szumlanski CL: Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52 (1999).
27. Schutz E, Gummert J, Mohr F, Oellerich M: Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341(8842), 436 (1993).
28. Leipold G, Schutz E, Haas JP, Oellerich M: Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 40(10), 1896-1898. (1997).
29. McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL: Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J. Pediatr. Hematol. Oncol. 22(5), 441-445 (2000).
30. Kurzawski M, Dziewanowski K, Ciechanowski K, Drozdzik M: Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A /*3C). Transpl. Int. 18(5). 623-625 (2005).
31. Szumlanski C, Otterness D, Her C et al.: Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15(1), 17-30 (1996).
32. Seki T, Tanaka T. Nakamura Y: Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum. Genet. 45(5), 299-302 (2000).
33. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE: Polymorphism of the thiopurine S-methyltransferase gene in African- Americans. Hum. Mol. Genet. 8(2), 371-376 (1999).
34. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA 92(4), 949-953. (1995).
35. Otterness D, Szumlanski C, Lennard L et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62(1), 60-73. (1997).
36. Tai HL, Krynetski EY, Yates CR et al.: Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58(4), 694-702. (1996).
37. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N et al.: Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum. Mutat. 12(3), 177-185 (1998).
38. Schaeffeler E, Stanulla M, Greil J et al.: A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukaemia 17(7), 1422-1424 (2003).
39. Hamdan-Khalil R, Allorge D, Lo-Guidice JM et al.: In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem Biophys Res. Commun. 309(4), 1005-1010 (2003).
40. Lindqvist M, Haglund S, Almer S et al.: Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 14(4), 261-265 (2004).
41. Schaeffeler E, Fischer C, Brockmeier D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14(7), 407-417 (2004).
42. Hamdan-Khalil R, Gala JL, Allorge D et al.: Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem. Pharmacol. 69(3), 525-529 (2005).
43. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE: Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94(12), 6444-6449 (1997).
44. Tai HL, Fessing MY, Bonten EJ et al.: Enhanced proteasomal degradation of mutant human thiopurine S- methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 9(5), 641-650 (1999).
45. Alves S, Amorim A, Ferreira F, Prata MJ: Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol. Ther. 70(2), 165-174. (2001).
46. Yan L, Zhang S, Eiff B et al.: Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther. 68(2), 210-219 (2000).
47. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 125(4), 879-887. (1998).
48. Marinaki AM, Arenas M, Khan ZH et al.: Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 13(2), 97-105 (2003).
49. Arenas M, Simpson G, Lewis CM et al.: Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin. Chem. 51(12), 2371-2374 (2005).
50. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 336(8709), 225-229 (1990).
51. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M: Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther. Drug Monit. 18(3), 228-233 (1996).
52. Arenas M, Duley JA, Ansari A et al.: Genetic determinants of the pre and postazathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides Nucleic Acids 23(8-9), 1403-1405 (2004).
53. Brouwer C, De Abreu RA, Keizer-Garritsen JJ et al.: Thiopurine methyltransferase in acute lymphoblastic leukemia: biochemical and molecular biological aspects. Eur. J. Cancer 41(4), 613-623 (2005).
54. Ford L, Prout C, Gaffney D, Berg J: Whose TPMT activity is it anyway? Ann. Clin. Biochem. 41 (Pt 6), 498-500 (2004).
55. Leipold G, Schutz E, Haas JP, Oellerich M: Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum. 40(10), 1896-1898 (1997).
56. Sebbag L, Boucher P, Davelu P et al.: Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 69(7), 1524-1527. (2000).
57. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008. (1999).
58. Marinaki AM, Ansari A, Duley JA et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14(3), 181-187 (2004).
59. Gearry RB, Roberts RL, Barclay ML, Kennedy MA: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14(11), 779-781 (2004).
60. Colombel JF, Ferrari N, Debuysere H et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6), 1025-1030 (2000).
61. Cummins D, Sekar M, Halil O, Banner N: Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 61(11), 1661-1662 (1996).
62. Gilissen LP, Bierau J, Derijks LJ et al.: The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 22(7), 605-611 (2005).
63. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y: Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment. Pharmacol. Ther. 16(1), 79-85. (2002).
64. Cuffari C, Hunt S, Bayless T: Utilization of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48(5), 642-646 (2001).
65. Chocair P, Duley J, Simmonds HA et al.: Low-dose allopurinol plus azathioprine/cyclosporine/prednisolone, a novel immunosuppressive regimen. Lancet 342(8863), 83-84 (1993).
66. Sparrow MP, Hande SA, Friedman S et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 22(5), 441-446 (2005).
67. Dubinsky MC, Lamothe S, Yang HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000).
68. Lowry PW, Franklin CL, Weaver AL et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49(5), 665-670 (2001).
69. Wright S, Sanders DS, Lobo AJ, Lennard L: Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53(8), 1123-1128 (2004).
70. Duley JA, Florin TH: Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27(5), 647-654 (2005).
71. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20(6), 593-599 (2004).
72. Marra CA, Esdaile JM, Anis AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29(12), 2507-2512 (2002).
73. Tavadia SM, Mydlarski PR, Reis MD et al.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J. Am. Acad. Dermatol. 42(4), 628-632 (2000).
74. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100(10), 2239-2247 (2005).
75. Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19(3), 147-151 (2005).
76. von Ahsen N, Armstrong VW, Oellerich M: Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C. Clin. Chem. 50(9), 1528-1534 (2004).
77. Brouwer C, Marinaki AM, Lambooy LH, Duley JA, Shobowale-Bakre M, De Abreu RA: Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene. Leukaemia 15(11), 1792-1793 (2001).
78. Dervieux T, Meyer G, Barham R et al.: Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin. Chem. 51 (11), 2074-2084 (2005).
79. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ: ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 54(11), 1664 (2005).
80. Vanderheiden BS: Inosine triphosphate in human erythrocytes: a genetic trait. In: Proc. Xth Congress Int. Soc. Blood Transf. Stockholm, Sweden (1964).
81. Sumi S, Marinaki AM, Arenas M et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111(4-5), 360-367 (2002).
82. Heller T, Oellerich M, Armstrong VW, von Ahsen N: Rapid detection of ITPA 94C>A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency. Clin. Chem. 50(11), 2182-2184 (2004).
83. Cao H, Hegele RA: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency, J. Hum. Genet. 47(11), 620-622 (2002).
84. Marsh S, King CR, Ahluwalia R, McLeod HL: Distribution of ITPA P32T alleles in multiple world populations. J. Hum. Genet. 49(10), 579-581 (2004).
85. Maeda T, Sumi S, Ueta A et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol. Genet. Metab. (2005).
86. Marinaki AM, Sumi S, Arenas M et al.: Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population. Nucleosides Nucleotides Nucleic Acids 23(8-9), 1399-1401 (2004).
87. von Ahsen N, Armstrong VW, Behrens C et al.: Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective crohn disease study. Clin. Chem. 51(12), 2282-2288 (2005).
88. Allorge, D, Hamdan R, Broly F, Libersa C, Colombel JF: ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/ 6-mercaptopurine induced myelosuppression. Gut 54(4), 565 (2005).
89. Breen DP, Marinaki AM, Arenas M, Hayes PC: Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 11(7), 826-833 (2005).
90. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA: Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 142-145 (1995).
91. Guerciolini R, Szumlanski C, Weinshilboum RM: Human liver xanthine oxidase: nature and extent of individual variation. Clin. Pharmacol. Ther. 50(6), 663-672 (1991).
92. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115(4), 813-821 (1998).
93. Collie-Duguid ES, Pritchard SC, Powrie RH et al.: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9(1), 37-42 (1999).
94. Kurzawski M, Gawronska-Szklarz B, Drozdzik M: Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther. Drug Monnit. 26(5), 541-545 (2004).
95. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J: Detection of one single mutation predicts thiopurine S- methyltransferase activity in a population of Saami in northern Norway. Clin. Pharmacol. Ther. 70(2), 183-188. (2001).
96. Indjova D, Atanasova S, Shipkova M, Armstrong VW, Oellerich M, Svinarov D: Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the bulgarian population. Ther. Drug Monit. 25(5), 631-636 (2003).
97. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM: Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur. J. Clin. Pharmacol 57(1), 51-54. (2001).
98. Boson WL, Romano-Silva MA, Correa H, Falcao RP, Teixeira-Vidigal PV, De Marco L: Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J. 3(3), 178-182 (2003).
99. Reis M, Santoro A, Suarez-Kurtz G: Thiopurine methyltransferase phenotypes and genotypes in Brazilians. Pharmacogenetics 13(6), 371-373 (2003).
100. Larovere LE, de Kremer RD, Lambooy LH, De Abreu RA: Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann. Clin. Biochem. 40(Pt 4), 388-393 (2003).
101. Isaza C, Henao J, Lopez AM, Cacabelos R: Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population. Methods Find. Exp. Clin. Pharmacol. 25(6), 423-429 (2003).
102. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8(2), 367-370. (1999).
103. McLeod HL, Pritchard SC, Githang'a J et al.: Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9(6), 773-776. (1999).
104. Kumagai K, Hiyama K, Ishioka S et al.: Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 11(3), 275-278. (2001).
105. Kubota T, Chiba K: Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br. J. Clin. Pharmacol. 51(5), 475-477. (2001).
106. Zhang JP, Guan YY, Xu AL et al.: Gene mutation of thiopurine S-methyltransferase in Uygur Chinese. Eur. J. Clin. Pharmacol. 60(1), 1-3 (2004).
107. Zhang JP, Guan YY, Wu JH, Jiang WQ, Huang M: Genetic polymorphism of the thiopurine S-methyltransferase of healthy Han Chinese. Ai Zheng 22(4), 385-388 (2003).
108. Chang JG, Lee LS, Chen CM et al.: Molecular analysis of thiopurine S-methyltransferase alleles in Southeast Asian populations. Pharmacogenetics 12(3), 191-195 (2002).
109. Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC: Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 24(5), 353-359 (2002).
110. Lu Y, Kham SK, Tan PL, Quah TC, Heng CK, Yeoh AE: Arrayed primer extension: a robust and reliable genotyping platform for the diagnosis of single gene disorders: β-thalassemia and thiopurine methyltransferase defeciency. Genet. Test. 9(3), 212-219 (2005).